Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery

New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™ , a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific  and Inductive Bio . ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management.

PRNewsWire • May 26, 2026

Ginkgo Bioworks: Another Lost Year

Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs but refuses to provide revenue guidance, causing analyst estimates to fall further. DNA continues to burn significant cash, with Q1 cash burn at $49M and 2026 guidance of $125M–$150M, leaving $373M in cash and no debt but weakening flexibility.

Seeking Alpha • May 13, 2026

Ginkgo Bioworks Q1 Earnings Call Highlights

Ginkgo Bioworks NYSE: DNA said it is sharpening its 2026 focus on autonomous laboratories after completing the divestiture of its biosecurity business and reporting lower year-over-year cash burn in the first quarter.

MarketBeat • May 10, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2026 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab

Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.

PRNewsWire • May 7, 2026

Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation

Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026 BOSTON, April 30, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2026, on Thursday, May 7, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.

PRNewsWire • Apr 30, 2026

Ginkgo Bioworks Launches Ginkgo Cloud Lab, Powered by Autonomous Lab Infrastructure

BOSTON, March 2, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced the official launch of Ginkgo Cloud Lab. This new interface allows researchers to transition their benchwork to Ginkgo's autonomous lab infrastructure directly through a web browser.

PRNewsWire • Mar 2, 2026

Ginkgo Bioworks Makes Major Pivot

Ginkgo Bioworks reported Q4 revenues of $33 million, down 24% year-over-year, and missing estimates by over $4 million. Cell Engineering, expected to drive growth, delivered just $125 million in 2025 revenue, far below the original $1.1 billion SPAC projection. Management is pivoting by selling the Biosecurity segment, retaining only a minority stake in the new private entity.

Seeking Alpha • Mar 2, 2026

Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 28, 2026

Ginkgo Bioworks Pivots To AI And Robotics After Rough Quarter

Ginkgo Bioworks (NYSE: DNA) shares are down following the company's fourth-quarter and full-year 2025 financial report.

Benzinga • Feb 27, 2026